Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

ACT IV trial investigators

Research output: Contribution to journalArticlepeer-review

513 Scopus citations

Fingerprint

Dive into the research topics of 'Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences